ReviewEuropean journal of heart failure2023
Autonomic and respiratory consequences of altered chemoreflex function: clinical and therapeutic implications in cardiovascular diseases.
Review in European journal of heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Trial
- Effect of a new resistance training method on the metaboreflex in cardiac rehabilitation patients: a randomized controlled trial.European journal of applied physiology · 2024Trial
- Anti-Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea.Chronic diseases and translational medicine · 2026Review
- Obstructive Sleep Apneas and Cardiovascular Diseases.Clocks & sleep · 2026Review
- Mechanisms Linking Sleep-Disordered Breathing and Cardiometabolic Disease Risk.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Vagal Activity and Fat Oxidation Basal Correlates in Older Active Postmenopausal Women: A Cross-Sectional Study.Sports medicine - open · 2026Article
- Cardiac autonomic function in bronchiectasis and age and gender-matched healthy participants: case-control study.Scientific reports · 2026Article
- Neuro-glial mechanisms underlying sex-based resilience to cardiorespiratory dysfunction in heart failure.Clinical science (London, England : 1979) · 2026Article
- Retrotrapezoid nucleus chemoreception: mechanisms of function and contributions to disordered breathing in disease.Trends in neurosciences · 2025Review
- New Insights of Cardiac Arrhythmias Associated with Sleep-Disordered Breathing: From Mechanisms to Clinical Implications-A Narrative Review.Journal of clinical medicine · 2025Review
- Review
- Neurocardiology: translational advancements and potential.The Journal of physiology · 2025Review
- 2024 update in heart failure.ESC heart failure · 2025Review
- The chronobiology of human heart failure: clinical implications and therapeutic opportunities.Heart failure reviews · 2025Review
- Hypoxic responsiveness and gut fermentation capacity in heart failure patients: preliminary results.Frontiers in physiology · 2025Article
- Interaction of simultaneous hypoxia and baroreflex loading on control of sympathetic action potential subpopulations.Journal of neurophysiology · 2024Article
- Effects of High-Intensity Interval Training Using the 3/7 Resistance Training Method on Metabolic Stress in People with Heart Failure and Coronary Artery Disease: A Randomized Cross-Over Study.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 6 countries.
Funding
Abstract
The importance of chemoreflex function for cardiovascular health is increasingly recognized in clinical practice. The physiological function of the chemoreflex is to constantly adjust ventilation and circulatory control to match respiratory gases to metabolism. This is achieved in a highly integrated fashion with the baroreflex and the ergoreflex. The functionality of chemoreceptors is altered in cardiovascular diseases, causing unstable ventilation and apnoeas and promoting sympathovagal imbalance, and it is associated with arrhythmias and fatal cardiorespiratory events. In the last few years, opportunities to desensitize hyperactive chemoreceptors have emerged as potential options for treatment of hypertension and heart failure. This review summarizes up to date evidence of chemoreflex physiology/pathophysiology, highlighting the clinical significance of chemoreflex dysfunction, and lists the latest proof of concept studies based on modulation of the chemoreflex as a novel target in cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.